跳至主要内容
临床试验/NCT05062681
NCT05062681Unknown4 期

Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow

Cairo University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年9月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
60
试验地点
1
主要终点
28 days in hospital mortality

研究概览

简要总结

This study aims to evaluate the therapeutic activity and side effects of 16 mg/day dexamethasone in comparison to equivalent dose of MP (1mg/kg/day)for the management of COVID-19 infected patients.Moreover, and according to the importance of the IL-6/STAT-3 in triggering the inflammatory cascade and as the miRNAs are considered as prognostic markers, hence, the study aims also to study the impact of the used regimens on these biomarkers

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult (≥18 years of age) at time of enrolment
  • Present COVID-19 (infection confirmed by RT-PCR or antigen testing)
  • Postive pressure ventilation (non-invasive or invasive) or need supplemental oxygen with non-rebreather mask
  • Admission to ICU in the last 24 hours

排除标准

  • 1- Underlying disease requiring chronic corticosteroids 2- Any dose of dexamethasone during the present hospital stay for COVID-19 for ≥5 days before enrollment 3- Systemic corticosteroids during present hospital stay for conditions other than COVID-19 (e.g. septic shock) 4-Any contraindication for corticosteroid administration 5-Cardiac arrest before ICU admission 6-Pregnancy or breast feeding 7- Immunocompromised patients as cancer (active) patients, patients on chemotherapy or radiotherapy, HIV, and transplant patients

研究组 & 干预措施

Dexamethasone group

Active Comparator

Patients will receive dexamethasone 8 mg q12hours

干预措施: Dexamethasone (Drug)

methylprednisolone group

Experimental

Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes

干预措施: Methylprednisolone (Drug)

结局指标

主要结局

28 days in hospital mortality

时间窗: 28 days

all patients who will die in 28 days from the start of treatment

次要结局

  • WHO clinical progression scale(10 days)
  • Adverse events related to steroids(10 days)
  • Duration of ICU stay(10 days)
  • Duration of high oxygen supplementation(10 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Eman Osama Zayed Mahmoud Rostom

teaching assistant

Cairo University

研究点 (1)

Loading locations...

相似试验